KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt Ratio (2016 - 2025)

Historic Debt Ratio for Halozyme Therapeutics (HALO) over the last 14 years, with Q3 2025 value amounting to 0.68.

  • Halozyme Therapeutics' Debt Ratio fell 422.76% to 0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68, marking a year-over-year decrease of 422.76%. This contributed to the annual value of 0.73 for FY2024, which is 1563.55% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Debt Ratio stood at 0.68 for Q3 2025, which was down 422.76% from 0.73 recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Debt Ratio peaked at 0.88 during Q1 2023, and registered a low of 0.06 during Q2 2022.
  • Its 5-year average for Debt Ratio is 0.59, with a median of 0.73 in 2025.
  • Its Debt Ratio has fluctuated over the past 5 years, first soared by 148642.17% in 2021, then plummeted by 3603.07% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Debt Ratio stood at 0.79 in 2021, then grew by 3.03% to 0.82 in 2022, then grew by 5.76% to 0.86 in 2023, then fell by 15.64% to 0.73 in 2024, then dropped by 6.8% to 0.68 in 2025.
  • Its Debt Ratio was 0.68 in Q3 2025, compared to 0.73 in Q2 2025 and 0.69 in Q1 2025.